Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875973 · ClinicalTrials.gov registry record · Phase 3
Pelacarsen Roll-over Extension Program
A Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
- 20
- Study locations
NCT06875973 is a Phase 3 study of Atherosclerotic Cardiovascular Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 599 participants, below the 7,539-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06875973, a Phase 3 study of Atherosclerotic Cardiovascular Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
- 20
- Study locations
Study Summary
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
Conditions Studied
Interventions
- DRUG Pelacarsen (TQJ230)
Study Locations (20)
Florida
- Excel Medical Clinical Trials LLC - Boca Raton
- C and A Clinical Trials - Cape Coral
- Proactive Clinical Research - Fort Lauderdale
- Proactive Clinical Research - Fort Lauderdale
- National Research Institute - Hialeah
- Sister Life Research Inc - Hialeah
- Zenith Clinical Research - Hollywood
- Columbus Clinical Services LLC - Miami
- Finlay Medical Research - Miami
- Infinite Clinical Research - Miami
California
- National Heart Institute - Beverly Hills
- Hope Clinical Research - Canoga Park
- Valley Clinical Trials Inc - Covina
- NICRs Research Center - Garden Grove
- Long Beach Clinical Trials - Long Beach
- Angel City Research Inc - Los Angeles
- California Medical Research Associates Inc - Northridge
- Stanford Health Care - Stanford
Alabama
- Parkway Medical Center - Birmingham
Arkansas
- Cardiology and Medicine Clinic PA - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2030-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06875973
The ClinicalTrials.gov registry entry for NCT06875973 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,539-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (92% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Pelacarsen (TQJ230) is the first listed.
NCT06875973 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06875973 about?
NCT06875973 is a clinical study titled "Pelacarsen Roll-over Extension Program". This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
What is the current status of trial NCT06875973?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2025-05-19. Estimated completion is 2030-12-08.
What conditions does trial NCT06875973 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06875973?
The interventions under investigation include: Pelacarsen (TQJ230) (DRUG).
Who is sponsoring clinical trial NCT06875973?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875973 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.